Parametric Portfolio Associates’s Immunovant IMVT Stock Holding History

Parametric Portfolio Associates’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$75K	Sell	13,590 -111,864	-89%	-$697K	﹤0.01%	3598
2021 Q4	$1.07M	Sell	125,454 -4,686	-4%	-$38.7K	﹤0.01%	2751
2021 Q3	$1.13M	Buy	130,140 +23,608	+22%	+$213K	﹤0.01%	2748
2021 Q2	$1.13M	Buy	106,532 +85,241	+400%	+$1.19M	﹤0.01%	2712
2021 Q1	$342K	Sell	21,291 -13,912	-40%	-$367K	﹤0.01%	3665
2020 Q4	$1.63M	Sell	35,203 -882	-2%	-$40.8K	﹤0.01%	2797
2020 Q3	$1.27M	Buy	+36,085	New	+$1.09M	﹤0.01%	2769

Other funds holding IMVT

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Parametric Portfolio Associates's IMVT Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Immunovant (IMVT) stake by 89% in Q1 2022, selling an estimated $697K and leaving 13,590 shares worth $75K. The position accounts for ﹤0.01% of the portfolio, ranked #3598.

Parametric Portfolio Associates first reported a position in IMVT in Q3 2020 and has held it in 7 quarters since. The position peaked at $1.63M in Q4 2020. 112 funds tracked by Wall St. Rank hold IMVT as of Q1 2022.

Parametric Portfolio Associates held 13,590 shares of Immunovant worth $75K as of Q1 2022.
Parametric Portfolio Associates sold 111,864 Immunovant shares in Q1 2022, an estimated $697K.
Immunovant made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3598 holding.
Parametric Portfolio Associates first reported a position in Immunovant in Q3 2020 and has held it in 7 quarters since.
Parametric Portfolio Associates's Immunovant position peaked at $1.63M in Q4 2020.
112 funds tracked by Wall St. Rank held Immunovant as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.